---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-085185"
form_type: "8-K"
ticker: null
cik: "0001845459"
company_name: "NKGen Biotech, Inc."
filed_at: "2024-10-04T23:59:59+00:00"
generated_at: "2026-05-30T20:39:56.701544+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# NKGen Biotech appoints Michael Klowden and Kathleen Scott as directors

## Summary
- Michael Klowden appointed Class II director until 2025 annual meeting; also joins Audit and Compensation Committees and chairs N&CG Committee.
- Kathleen Scott appointed Class III director until 2026 annual meeting; chairs Audit and Compensation Committees and serves on N&CG Committee.
- Both directors will receive deferred non-employee director compensation, paid when Company meets funding goals.
- No arrangements or related transactions exist between new directors and Company per Reg S-K Item 404(a).

## SEC filing metadata
- accession: 0001213900-24-085185
- form_type: 8-K
- cik: 0001845459
- company_name: NKGen Biotech, Inc.
- filed_at: 2024-10-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845459/000121390024085185/0001213900-24-085185-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845459/000121390024085185/ea0216761-8k_nkgen.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-085185
- JSON: https://secwatch.observer/filing/0001213900-24-085185.json
- Plain text: https://secwatch.observer/filing/0001213900-24-085185.txt

## Key facts
- Executive change
  Kathleen Scott was elected as Director at NKGen Biotech, Inc..
  - Action: elected
  - Role: Director
  source text: The Board following a recommendation from the N&CG Committee, also unanimously elected to have Kathleen Scott fill, effective immediately, the Class III director vacancy created by her resignation
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845459/000121390024085185/0001213900-24-085185-index.htm
- Executive change
  Michael Klowden was elected as Director at NKGen Biotech, Inc..
  - Action: elected
  - Role: Director
  source text: On October 3, 2024, the Board of Directors (the “Board”) of NKGen Biotech Inc. (the “Company”), following a recommendation from the Nomination and Corporate Governance Committee (the “N&CG Committee”), unanimously elected to have Michael Klowden fill, effective immediately, the Class II director vacancy
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845459/000121390024085185/0001213900-24-085185-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.